Topline data from Phase 2a trial of tegoprubart in ALS expected in 2Q 2022 Ongoing clinical studies evaluating tegoprubart in kidney transplantation, IgA nephropathy, and islet cell transplantation with initial readouts anticipated in late 2022 Cash balance of $84.8M, sufficient to fund operations into 2024 Conference call today at 4:30… Read More..

TORONTO, Ontario and CAMBRIDGE, MA , March 24, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it will be… Read More..

Reports Strongest Quarterly Revenue and Operating Income in Q4 2021 Since the Pandemic Began SAN FRANCISCO, CA, March 24, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire --American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and… Read More..